What does it cost to live with illness?
Gharama brings health-financing data, research and lived costs together to make the financial burden of chronic illness visible — and turn that evidence into better public health policy.
of Kenya's current health expenditure came from out-of-pocket payments in 2023.
From the price of care to the policies that change it.
GHARAMA examines how healthcare is financed and what people pay for long-term treatment. Our focus is hypertension, diabetes and heart failure.
Explore published country indicators, understand their limits, and investigate interventions such as medicine subsidies and improved outpatient coverage. Policy scenarios are illustrative, not claims of proven impact.
Explore the evidence.
Compare countries, examine policy options or calculate personal expenses.
Compare health spending
See how much healthcare expenditure is paid directly by households across countries.
From evidence to action
Identify policy questions, intervention options and measurable outcomes for chronic illness.
Understand personal costs
Calculate medicine, transport, visits, lost income and other household expenses.
What households pay.
Compare out-of-pocket payments as a share of all current health expenditure. These are health-system indicators, not disease-specific treatment costs.
Country comparison
Bars show reported observations from different years. They should not be interpreted as a single-year ranking. Countries without a verified value in this dataset are not plotted.
This is a share of total health spending, not the percentage of an individual patient's income.
National out-of-pocket spending cannot establish what a patient with diabetes or hypertension pays. Disease-level research is needed for that.
See all available observations
| Country | Out-of-pocket share | Year |
|---|
How has household-financed spending changed?
Select a country in Explore, then load its reported annual series from the World Bank. The years and values below are reported figures, not projections.
Select a country and load its history (internet required)
From evidence to better policy.
Understand what a statistic can tell us, what it cannot, and how public health interventions could be designed and evaluated.
A national financing indicator
Measure outcomes, not intentions
Turn a promising idea into a testable intervention.
Choose a policy approach. Gharama outlines the delivery mechanism, implementation risks, equity considerations and evidence needed before a recommendation can be made.
What might a subsidy change?
A transparent arithmetic illustration, not a forecast or measured intervention effect. Enter your own assumptions; no national spending figure is used to infer a patient's treatment cost.
Assumes 100% uptake, fixed prices, full subsidy delivery and no administration costs, behavioural changes or supply constraints. Does not estimate health outcomes or cost-effectiveness.
What does the research support?
Condition-specific, linked guidance. This is clinical and implementation evidence—not proof that a particular financing intervention will save money in your selected country.
A research plan you can use.
Turn a policy idea into a testable question with an implementation pathway, evaluation design, safeguards and the evidence still needed.
How would we know it worked?
Suggested indicators for a pilot. Baselines and targets must be established locally, not inferred from national expenditure shares.
What published guidance supports—and what still needs testing.
A carefully scoped evidence register. Clinical and implementation guidance is not proof that a subsidy saves money or improves outcomes in a particular country.
| Focus | Published source | What it supports | What it cannot establish |
|---|---|---|---|
| Hypertension | WHO pharmacological treatment guideline (2021) | Evidence-based treatment approaches and follow-up recommendations | Local medication prices or effects of a proposed subsidy |
| Primary care delivery | WHO HEARTS risk-based CVD management (2020) | A framework for strengthening cardiovascular care in primary health systems | Cost-effectiveness in a specific setting without evaluation |
| Medicine access | WHO HEARTS essential medicines and technology | Procurement, distribution and medicine supply management considerations | Actual retail prices, stock-out rates or patient savings |
| Financial protection | WHO / World Bank national health accounts | Share of national current health expenditure paid directly by households | Individual financial hardship or condition-specific costs |
Policy implementation workbench
Build an explicit policy hypothesis, test the budget assumptions and identify what must be measured before recommending scale-up. Figures below are user-defined scenarios, never observed programme effects.
What would it take to implement this?
Check which essential prerequisites are already in place. This is a planning checklist, not an independently assessed country score.
How sensitive is the proposal?
Uses your existing scenario assumptions. Change the uptake rate and administration overhead to examine programme expenditure.
All amounts are in the unspecified currency entered in the policy scenario. Excludes behavioural changes, clinical effects, price changes and other programme costs.
What evidence would change a policy decision?
| Question | Indicator | Suggested source | Interpretation |
|---|
What does care cost you?
A private, on-device calculator for monthly healthcare expenses. Your entries are not uploaded or stored on a server.
Direct expenses + lost income − reimbursements
This is a personal estimate, not a clinical or economic diagnosis. It excludes costs you have not entered and should not be compared directly with national out-of-pocket expenditure shares.
Where the evidence comes from.
Good policy begins with knowing what the data actually measure. Gharama distinguishes published statistics, patient estimates and intervention hypotheses.
World Bank · WHO health expenditure data
Out-of-pocket expenditure (% of current health expenditure), indicator SH.XPD.OOPC.CH.ZS. The dataset embedded here is a curated snapshot with source years shown per observation.
WHO Global Health Expenditure Database
Underlying international health-expenditure accounting framework and country reporting.
Latest published figures
Check whether newer country figures are available. The figures already displayed remain available without an internet connection.
What Gharama does not claim
A national out-of-pocket share is not a measure of catastrophic health expenditure, treatment affordability, medicine prices, or the household cost of any specific disease.
No patient records, insurer claims or hospital pricing feeds are currently connected. No simulated patient data are presented as observations. Policy insights are structured hypotheses, not causal findings.
Peer-reviewed cost-of-illness studies, facility tariffs, medicine prices, insurance benefit schedules, household surveys and consented patient-reported costs. Each will need dataset-level citations, licensing checks and a clear methodology before publication.
The included figures are a dated reference snapshot. Check individual observations against the official source before citing them in academic or policy work. Online updates depend on connectivity.